Replies to post #36254 on Relief Therapeutics Holding AG (RLFTF)

[ratna1]

ChangesIV, let me take the opportunity to express my sincere and heartfelt gratitude for your untiring research. It is not going wasted!
I copy and paste it to all my colleagues and practitioners at the university teaching hospital here.As a medical anthropologist I am not on the frontline bút do advise and counsel front line intensive care personell, general practitioners, researchers and maybe most useful the designers of the hygenic concepts and intensiv care environments .

It is amazing that AVIPTADIL has been used in it's inhalation form here at the university hospital for pneumonia resulting from intensive chemotherapy with great success for years as published in the NEJM but the ICU 2 blocks down from the oncology campus is not aware of its use at all.

Sometimes I feel more like an evangelist than anything else with an endless effort to overcome the conditioned reflex of doubting anything that appears to be positive ...

Also the company ADVITA which RLF is going to buy up with shares only is domiciled here and has been supplying these clinical trials with inhalation devices

FYI

https://www.uniklinik-freiburg.de/presse/pressemitteilungen/detailansicht/2058-hormon-inhalation-stoppt-schwere-nebenwirkung-von-immun-krebstherapie.html

Original-Titel der Publikation:
Vasoactive Intestinal Peptide in Checkpoint Inhibitor–Induced Pneumonitis

DOI: 10.1056/NEJMc2000343

Link zur Studie:https://www.nejm.org/doi/10.1056/NEJMc2000343

Kontakt:
Prof. Dr. Joachim Müller-Quernheim
Ärztlicher Direktor
Klinik für Pneumologie
Universitätsklinikum Freiburg
Telefon: [phone]
[e-mail]